User login

Enter your username and password here in order to log in on the website:
Choose language: English | Deutsch

vwd up-to-date–
news, dates, events

News

Events

Title
Date
Location
Category
FISD Technology Forum
27.02.2020
London
Exhibitions and Congresses

Meet our colleagues Ricky Strachan and  Richard Burtsal at FISD Technology Forum! Click here for more information.

 

Branchentag IT
27.02.2020
Frankfurt
Exhibitions and Congresses

On Thursday, 27 February 2020 from 10:30 to 14:30, interested professionals have the opportunity to introduce themselves personally to us at the Career Information Centre - Main-BiZ. Please bring your complete, meaningful application documents with you.

You can get an overview of our open positions here.

 

FIX EMEA Trading Conference 2020
12.03.2020
London
Exhibitions and Congresses

The EMEA Trading Conferenceis Europe’s largest one-day electronic trading event. The event will cover the most pressing issues facing the institutional trading community and provide a neutral platform for buy-side, sell-side, exchanges, vendors and regulators to share their ideas on how the community can continue to collaborate. Designed to appeal to all asset classes, the agenda will maintain a great balance of topics across multiple asset classes.

Our colleagues Ricky Strachan, Ken Riggio and Richard Burtsal are looking forward to meeting you at booth D7!

BVI Fund Operations Conference
31.03.2020
Frankfurt
Exhibitions and Congresses

The BVI Fund Operations Conference will inform you about the trends in the securities and fund industry on 31 March 2020 in Cape Europe - with more than 40 presentations in parallel tracks.

In addition, you can expect interesting presentations on topics such as sustainability, digitization, information security, financial market data, trading, regulatory and investor reporting, real estate management and custodian issues.

Meet our colleagues Oliver Preisendörfer and Mark Seeber on site and take the opportunity to exchange experiences.

Further information about the event can be found here...

Amsterdam Tech Job Fair
23.04.2020
Amsterdam
Exhibitions and Congresses

When great people and great companies come together, amazing potential can be realized. Join the Tech Job Fair! Update your resume, and get ready for an interview with us. Here you'll find our current vacancies.

When?
23.04.2020, 18.00 - 21.00

Where?
Software Improvement Group
Fred. Roeskestraat 115
Amsterdam, 1076 EE Netherlands

konaktiva
12.05.2020
Darmstadt
Exhibitions and Congresses

Every year more than 11,000 students use konaktiva to get closer to an internship, a working student position and even their dream job.

Come by and get to know us! You are also welcome to make an appointment with us in advance. Please contact Stefanie Blasi by mail.

When?
12. May 2020, 09:30 - 16:30 o'clock

Where?
darmstadtium (Science and Congress Centre), Schloßgraben 1, 64283 Darmstadt, Germany

Who?
Students of all disciplines and universities

Visiting the fair is free of charge and does not require registration. The konaktiva is organised by a team of volunteer students.

Treffpunkt Kaiserslautern
13.05.2020
Kaiserslautern
Exhibitions and Congresses

Motivated graduates and students of all disciplines from universities and universities of applied sciences from all over southwest Germany have the opportunity to get to know what we have to offer and make their first contacts at the meeting point company contact fair in Kaiserslautern.

You will find us from 10.00 to 16.00 in building 42 of the TU Kaiserslautern. You are also welcome to arrange an appointment with us in advance. Please send an e-mail to Sandra Schintu.

 

 

 

DKF 2020, 10. D-A-CH Kongress für Finanzinformationen
14.05.2020
Munich
Exhibitions and Congresses

We will again be represented at the DKF this year and look forward to your visit to our stand.

Further information will be available here soon or on the official DKF 2020 website.

 Latest news on markets, economy and companies

Newsroom

Business Wire

Mynewsdesk

GlobeNewswire

11.09.2019 GlobeNewswire: Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis

Janssen reports new head-to-head Phase 3 study data show ponesimod superiority

versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple

sclerosis

 

• OPTIMUM Phase 3 study data presented for the first time during oral

presentation at the 35th Congress of The European Committee for Treatment and

Research in Multiple Sclerosis

 

 

• Idorsia Pharmaceuticals Ltd, J&J and Actelion Pharmaceuticals Ltd have

a Revenue Sharing Agreement in respect to ponesimod

 

Allschwil, Switzerland – September 11, 2019

Idorsia Ltd (SIX: IDIA) today informed that the Janssen Pharmaceutical

Companies of Johnson & Johnson announced the results from the Phase 3 OPTIMUM

study for ponesimod, an investigational selective S1P 1 receptor modulator,

showing superior efficacy on the primary endpoint and most secondary endpoints

compared to Aubagio ® (teriflunomide)* 14 mg in adults with relapsing multiple

sclerosis (MS).

 

For further details please read the full announcement available here:

 

www.janssen.com/new-head-head-phase-3-study-data-show-ponesimod-superiority-versus-aubagio-teriflunomide-14-mg

 

 

About the Revenue Sharing Agreement

Idorsia Pharmaceuticals Ltd, J&J and Actelion Pharmaceuticals Ltd have entered

into the Revenue Sharing Agreement in respect to ponesimod. Under the terms of

the Revenue Sharing Agreement, Idorsia Pharmaceuticals Ltd is entitled to

receive quarterly payments of 8% of the net sales of ponesimod products from

Actelion Pharmaceuticals Ltd.

 

* Aubagio ® is a registered trademark of Sanofi Société Anonyme France.

 

Notes to the editor

 

About Idorsia

Idorsia Ltd is reaching out for more - We have more ideas, we see more

opportunities and we want to help more patients. In order to achieve this, we

will develop Idorsia into one of Europe’s leading biopharmaceutical companies,

with a strong scientific core.

 

Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is

specialized in the discovery and development of small molecules, to transform

the horizon of therapeutic options. Idorsia has a broad portfolio of innovative

drugs in the pipeline, an experienced team, a fully-functional research center,

and a strong balance sheet – the ideal constellation to bringing R&D efforts to

business success.

 

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June

2017 and has over 750 highly qualified specialists dedicated to realizing our

ambitious targets.

 

For further information, please contact

Andrew C. Weiss

Senior Vice President, Head of Investor Relations & Corporate Communications

Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil

+41 (0) 58 844 10 10

www.idorsia.com

 

The above information contains certain 'forward-looking statements', relating

to the company's business, which can be identified by the use of

forward-looking terminology such as 'estimates', 'believes', 'expects', 'may',

'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks',

'pending' or 'anticipates' or similar expressions, or by discussions of

strategy, plans or intentions. Such statements include descriptions of the

company's investment and research and development programs and anticipated

expenditures in connection therewith, descriptions of new products expected to

be introduced by the company and anticipated customer demand for such products

and products in the company's existing portfolio. Such statements reflect the

current views of the company with respect to future events and are subject to

certain risks, uncertainties and assumptions. Many factors could cause the

actual results, performance or achievements of the company to be materially

different from any future results, performances or achievements that may be

expressed or implied by such forward-looking statements. Should one or more of

these risks or uncertainties materialize, or should underlying assumptions

prove incorrect, actual results may vary materially from those described herein

as anticipated, believed, estimated or expected.

 

 

 

Anhang Medienmitteilung PDF

Newsletter



Subscribe to our free newsletter and you will receive the latest information about our products and solutions.

 

Contact

 

Headquarter

vwd Vereinigte Wirtschaftsdienste GmbH
Mainzer Landstrasse 178 – 190
60327 Frankfurt am Main

Phone: +49 69 50701-0
E-mail: dialogue(at)vwd.com

 

Press

Your questions will be answered by
Christiane Kaczmarek-Schempp.

Phone: +49 69 50701-286
E-mail: ckaczmarek(at)vwd.com